EP1930041B1 - Kapsel für Pulvermedikament - Google Patents

Kapsel für Pulvermedikament Download PDF

Info

Publication number
EP1930041B1
EP1930041B1 EP08152808.5A EP08152808A EP1930041B1 EP 1930041 B1 EP1930041 B1 EP 1930041B1 EP 08152808 A EP08152808 A EP 08152808A EP 1930041 B1 EP1930041 B1 EP 1930041B1
Authority
EP
European Patent Office
Prior art keywords
capsule
opening
internal chamber
filling
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP08152808.5A
Other languages
English (en)
French (fr)
Other versions
EP1930041A3 (de
EP1930041A2 (de
Inventor
Paul Kenneth Rand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1930041A2 publication Critical patent/EP1930041A2/de
Publication of EP1930041A3 publication Critical patent/EP1930041A3/de
Application granted granted Critical
Publication of EP1930041B1 publication Critical patent/EP1930041B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the present invention relates to a capsule for holding a powder and is particularly, but not exclusively, concerned with such a capsule for containing a pharmaceutical powder, for instance an inhalable pharmaceutical powder.
  • Dry powder inhalation devices are well established for use in treating respiratory diseases.
  • the DISKUS® device of GlaxoSmithKline the pharmaceutical composition is formulated as a respirable powder and the powder is divided into a plurality of unit doses, each dose contained in its own sealed enclosure, for example blisters on a dosing strip.
  • the enclosures are opened, one at a time, by an opening mechanism of the inhalation device and the powder dose entrained into a patient's respiratory tract by an airflow generated through the device by the patient inhaling at a mouthpiece of the device.
  • Some of the sealed enclosures used in DPIs are difficult to fill with a unit dose of the pharmaceutical powder. It is an aim of the invention to provide a capsule for holding a powder which facilitates its filling with the powder.
  • a capsule for a powder having a body which is provided with an internal chamber to hold the powder and first and second openings to an exterior environment, the body adapted to be displaced from a filling state, in which the first and second openings are placed in fluid communication with one another through the internal chamber thereby enabling creation of an airflow through the body from the second opening to the first opening which is able to entrain powder in the exterior environment into the internal chamber for filling thereof, to a sealing state in which the internal chamber is sealed from the exterior environment so as to retain the powder held therein,
  • the body is a multi-part structure having first and second parts which are moved relative to one another to bring the body to its filling and sealing states, wherein the first part is partially plugged in the first opening in the filling state, the first part having a plug section which is located in the first opening in the filling state, the plug section having an outer surface which has first and second outer surface portions, wherein in the filling state the first outer surface portion is spaced from the inner surface of
  • Described is also a method of providing a capsule filled with a powder having the steps of providing a capsule according to the invention in its filling state, creating an airflow through the body of the capsule in a direction from the second opening to the first opening to cause powder from a powder source disposed externally of the capsule to be entrained into the internal chamber of the body, and moving the capsule to its sealing state.
  • the airflow through the capsule body may be created by applying a vacuum at the first opening of the capsule body.
  • FIGURES of drawings there is shown a generally cylindrical capsule 1 adapted to be filled with a powder product 2.
  • the capsule 1 has particular application for dry powder products, more particularly dry powder pharmaceutical formulations for inhalation by a patient.
  • the capsule 1 may be used in a dry powder inhaler.
  • the capsule 1 has a two-part construction comprising a generally cylindrical outer sleeve part 3 and a generally cylindrical inner piston part 5.
  • the capsule 1 is preferably made from air- and moisture-proof materials, especially if the powder 2 is hygroscopic, as is the case with many pharmaceutical powders. Where the capsule is for a pharmaceutical powder, the material is an inert pharmaceutically acceptable material.
  • the outer sleeve part 3 has an annular wall 8 having an outer circumferential surface 9 and an inner circumferential surface 11.
  • the inner circumferential surface 11 bounds an axial bore 13 which passes through the sleeve part 3 from an upper open end 15 to a lower open end 17.
  • the upper open end 15 has a countersunk entrance 27.
  • the inner circumferential surface 11 is shaped to define a restriction 19 in the bore 13 to divide the bore 13 into an upper section 21 and a lower section 23.
  • the restriction 19 in this embodiment takes the form of a step or shoulder which extends radially into the bore 13 to define an intermediate bore section 25 of narrower inner diameter than that of the upper and lower sections 21, 23.
  • the restriction 19 in the bore 13 is resiliently deformable such that, on application of a downward force thereon, it is able to be deflected downwardly towards the lower open end 17 and, on release of the downward force, it returns to its undeformed position. This allows the piston part 5 to be held in place in the sleeve part 3 in different sliding positions, and for a dynamic seal to be formed between the sleeve and piston parts 3, 5.
  • the sleeve part 3 is preferably made from a plastics material, for instance by a moulding process, such as injection moulding or micro-moulding.
  • the sleeve part 3 may have a length (height) in the range of about 5mm to about 15mm and an outer diameter in the range of about 3mm to about 8mm.
  • the capsule 1 may be referred to as a "microcapsule".
  • the bore 13 may have an inner diameter (in the upper and lower sections 21, 23) in the range of about 1 mm to about 6mm.
  • Such a capsule 1 is suited for holding a unit dose of a pharmaceutical powder in the range of about 2 ⁇ g to about 30mg.
  • the capsule 1 may contain a unit dose of pure active drug substance, or a blend of pure active drug substances, in the range of about 2 ⁇ g to about 250 ⁇ g (i.e. no bulk filler), or a bulked out unit dose of a pharmaceutical powder up to about 30mg.
  • the sleeve part 3 For a small unit dose of pharmaceutical powder, for instance in the range of about 2-250 ⁇ g, it is preferable for the sleeve part 3 to have a length (height) in the range of about 5mm to about 6mm, an outer diameter in the range of about 3mm to about 5mm, and an inner diameter in the range of about 1 mm to about 3mm, more preferably about 2mm.
  • the piston part 5 as shown in FIGURES 2 and 3 this has a shank 29 of a general cylindrical cross section.
  • the shank 29 has an upper section 31, a lower section 33 of smaller outer diameter than the upper section 31, and a flared section 35 connecting the upper and lower sections 31, 33.
  • a series of longitudinal grooves or flutes 37 is circumferentially arranged about a lower end portion 34 of the upper shank section 31.
  • the upper section 31 of the shank 29 has an outer diameter d1 which is the same, or, more typically, greater than the 'normal' inner diameter d2 of the intermediate section 25 of the bore 13 in the sleeve part 3.
  • the upper section 31 of the shank 29 fits in the intermediate section 25 with an interference fit, the resiliently deformable nature of the restriction 19 facilitating the formation of the interference fit, especially when the outer diameter d1 of the upper section 31 of the shank 29 is greater than the inner diameter d2 of the intermediate section 25 of the bore 13.
  • the inner diameter d2 of the intermediate bore section 25 is less than the outer diameter d1 of the upper shank section 31, as will be appreciated by a comparison of FIGURES 3 and 4 .
  • the piston part 5 is also preferably made from a plastics material, for instance by a moulding process, such as injection moulding or micro-moulding.
  • the piston part 5 is first slidably mounted in the sleeve part 3 in a filling position shown in FIGURE 1 .
  • the upper section 31 of the shank 29 of the piston part 5 is slidably received in the intermediate section 25 of the bore 13 so as to be held in frictional engagement therewith such that the longitudinal grooves 37 place the upper and lower bore sections 21,23 in fluid communication with one another.
  • the longitudinal grooves 37 have a longer longitudinal dimension than that of the intermediate section 25 of the bore 13. Placing the piston part 5 in the filling position spaces the piston head 39 above the upper open end 15 of the bore 13, as further shown in FIGURE 1 . In this way, an inlet path 41 into the upper section 21 of the bore 13 is defined.
  • the longitudinal grooves 37 are sized such that the powder particles 2 are occluded therein. This does not prevent the vacuum from creating the negative pressure in the upper bore section 21 in the filling position, but prevents the powder 2 from seeping from the upper bore section 21 to the lower bore section 23.
  • the grooves 37 may have a depth in the range of substantially 0.005-0.01 mm, preferably substantially 0.007 mm.
  • the piston part 5 When the dose of powder 2 in the upper bore section 21 is required to be discharged, the piston part 5 is slid upwardly to a discharge position shown in FIGURE 4 .
  • the piston head 39 In the discharge position of the piston part 5, the piston head 39 is spaced upwardly of the upper open end 15 of the sleeve part 3 and the lower section 33 of the shank 29 is positioned in the intermediate bore section 25.
  • an airflow path indicated by the arrows B is provided which enables the powder 2 in the upper bore section 21 to be discharged from the capsule 1 out of the upper open end 15 of the sleeve part 3.
  • the powder 2 may be discharged in this way by application of a positive air pressure to the bore 13 of the sleeve part 3 through the lower open end 17.
  • Appropriate medicaments for the inhalable pharmaceutical powder for use in the present invention may be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (e.g. as the sodium salt), ketotifen or nedocromil (e.g.
  • analgesics e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine
  • anginal preparations e.g., diltiazem
  • antiallergics e.g., cromoglycate (e.g. as the sodium salt), ketotifen or nedocromil (e.g.
  • antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine
  • antihistamines e.g., methapyrilene
  • anti- inflammatories e.g., beclomethasone (e.g. as the dipropionate ester), fluticasone (e.g. as the propionate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g.
  • antitussives e.g., noscapine
  • bronchodilators e.g., albuterol (e.g. as free base or sulphate), salmeterol (e.g. as xinafoate), ephedrine, adrenaline, fenoterol (e.g. as hydrobromide), formoterol (e.g.
  • bromide as bromide
  • tiotropium as bromide
  • atropine or oxitropium hormones, e.g., cortisone, hydrocortisone or prednisolone
  • xanthines e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline
  • therapeutic proteins and peptides e.g., insulin or glucagon
  • vaccines, diagnostics, and gene therapies as bromide
  • hormones e.g., cortisone, hydrocortisone or prednisolone
  • xanthines e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline
  • therapeutic proteins and peptides e.g., insulin or glucagon
  • vaccines diagnostics, and gene therapies.
  • the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
  • salts e.g., as alkali metal or amine salts or as acid addition salts
  • esters e.g., lower alkyl esters
  • solvates e.g., hydrates
  • Preferred medicaments are an anti-inflammatory agent (for example a corticosteroid or an NSAID), an anticholinergic agent, a ⁇ 2 -adrenoreceptor agonists, an antiinfective agent (e.g. an antibiotic or an antiviral) and an antihistamine.
  • the medicament may be the sole medicament in the capsule or in combination with another medicament. Preferred combinations are based on the preferred medicament list above.
  • Preferred as a component of a medicament combination in the capsule are albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
  • a particularly preferred medicament combination for use in the capsule of the invention is a bronchodilator in combination with an anti-inflammatory.
  • the bronchodilator is suitably a beta-agonist, particularly a long-acting beta-agonist (LABA).
  • Suitable bronchodilators include salbutamol (e.g., as the free base or the sulphate salt), salmeterol (e.g., as the xinafoate salt) and formoterol (eg as the fumarate salt).
  • the anti-inflammatory is suitably an anti-inflammatory steroid.
  • Suitable anti-inflammatory compounds include a beclomethasone ester (e.g., the dipropionate), a fluticasone ester (e.g., the propionate) or budesonide or any salt or solvate thereof.
  • a beclomethasone ester e.g., the dipropionate
  • fluticasone ester e.g., the propionate
  • budesonide or any salt or solvate thereof.
  • fluticasone propionate and salmeterol or any salt or solvate thereof (particularly the xinafoate salt).
  • a further preferred combination is budesonide and formoterol or any salt or solvate thereof (e.g. formoterol as the fumarate salt).
  • powdered medicament particles suitable for delivery to the bronchial or alveolar region of the lung have an aerodynamic diameter of less than 10 micrometers, preferably less than 6 micrometers. Other sized particles may be used if delivery to other portions of the respiratory tract is desired, such as the nasal cavity, mouth or throat.
  • the medicament may be delivered as a pure drug or together with excipients (carriers) which are suitable for inhalation. Suitable excipients include organic excipients such as polysaccharides (i.e. starch, cellulose and the like), lactose, glucose, mannitol, amino acids, and maltodextrins, and inorganic excipients such as calcium carbonate or sodium chloride. Lactose is a preferred excipient.
  • the excipient may be included with the medicament via well-known methods, such as by admixing, co-precipitating and the like.
  • Particles of the powdered medicament and/or excipient may be produced by conventional techniques, for example by micronisation, milling or sieving. Additionally, medicament and/or excipient powders may be engineered with particular densities, size ranges, or characteristics. Particles may comprise active agents, surfactants, wall forming materials, or other components considered desirable by those of ordinary skill.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (28)

  1. Kapsel (1) für ein inhalierbares pharmazeutisches Pulver (2) mit einem Körper, welcher mit einer inneren Kammer (21), um das Pulver zu halten, und einer ersten und einer zweiten Öffnungen (17, 15) zu einer äußeren Umgebung versehen ist, wobei der Körper angepasst ist, um aus einem Füllzustand, in welchem die erste und die zweite Öffnung durch die innere Kammer miteinander in Fluidverbindung platziert sind, wobei dadurch eine Erzeugung eines Luftstroms durch den Körper von der zweiten Öffnung (15) zu der ersten Öffnung ermöglicht wird, welcher imstande ist ein inhalierbares pharmazeutisches Pulver in der äußeren Umgebung in die innere Kammer zum Füllen von ihr mitzureißen, in einen Dichtzustand versetzt zu werden, in welchem die innere Kammer von der äußeren Umgebung abgedichtet ist, um das darin gehaltene Pulver zurückzuhalten,
    wobei der Körper eine mehrteilige Struktur mit einem ersten und einem zweiten Teil (5,3) ist, welche relativ zueinander bewegt werden, um den Körper in seinen Füll- und Dichtzustand zu bringen,
    wobei der erste Teil in dem Füllzustand teilweise in die erste Öffnung eingestöpselt ist, wobei der erste Teil einen Stöpselabschnitt (34) aufweist, welcher sich in dem Füllzustand in der ersten Öffnung befindet, der Stöpselabschnitt eine äußere Oberfläche (37) aufweist, welche einen ersten und einen zweiten äußeren Oberflächenabschnitt aufweist, wobei, in dem Füllzustand, der erste äußere Oberflächenabschnitt (37) von der inneren Oberfläche der ersten Öffnung beabstandet ist und der zweite äußere Oberflächenabschnitt an die innere Oberfläche der ersten Öffnung anstößt, wobei der erste äußere Oberflächenabschnitt einem oder mehr Kanälen (37) in der äußeren Oberfläche des Stöpselabschnitts entspricht,
    wobei der eine oder mehr Kanäle Längsnuten oder -rillen aufweist, und die Nuten oder Rillen eine Tiefe in dem Bereich von 0,005mm - 0,01mm aufweisen, derart dass die inhalierbaren pharmazeutischen Pulverpartikel darin okkludiert werden,
    wobei der erste Teil in dem Füllzustand die erste Öffnung teilweise versperrt, in einem Ausmaß, welches einen Luftstrom durch sie hindurch gestattet, aber welche mit dem in dem Luftstrom mitgerissenen inhalierbaren pharmazeutischen Pulver okkludiert wird.
  2. Kapsel nach Anspruch 1, bei welcher der Füll- und der Dichtzustand ein ausgedehnter beziehungsweise ein zusammengezogener Zustand des Körpers ist.
  3. Kapsel nach Anspruch 1 oder Anspruch 2, bei welcher der Körper in beiden, dem Füll- und dem Dichtzustand zusammengebaut ist.
  4. Kapsel nach Anspruch 1, 2 oder 3, wobei in dem Füll- und dem Dichtzustand der erste Teil an dem zweiten Teil montiert ist.
  5. Kapsel nach Anspruch 1, 2, 3 oder 4, wobei in dem Dichtzustand der erste Teil in einer ersten Position relativ zu dem zweiten Teil angeordnet ist, in welcher er die erste und die zweite Öffnung abdichtend verschließt, und wobei in dem Füllzustand der erste Teil in einer zweiten Position relativ zu dem zweiten Teil angeordnet ist, in welcher er die erste und die zweite Öffnung öffnet.
  6. Kapsel nach Anspruch 1, bei welcher der Stöpselabschnitt ein erster Stöpselabschnitt ist, und der erste Teil einen zweiten Stöpselabschnitt aufweist, welcher die erste Öffnung in dem Dichtzustand abdichtend verstöpselt.
  7. Kapsel nach Anspruch 6, bei welcher der Körper aus dem Füllzustand in den Dichtzustand durch eine Bewegung des ersten Teils in eine erste Richtung relativ zu dem zweiten Teil bewegt wird, wobei der erste Stöpselabschnitt bei Verwendung an dem ersten Teil in der ersten Richtung relativ zu dem zweiten Stöpselabschnitt angeordnet ist.
  8. Kapsel nach Anspruch 6 oder 7, bei welcher der erste und der zweite Stöpselabschnitt angrenzend angeordnet sind.
  9. Kapsel nach Anspruch 5, oder einem der Ansprüche 6 bis 8, bei Abhängigkeit von Anspruch 5, bei welcher der erste Teil in dem Dichtzustand die zweite Öffnung abdichtend verstöpselt.
  10. Kapsel nach einem der Ansprüche 1 bis 4, bei welcher die erste Öffnung in dem zweiten Teil ausgebildet ist.
  11. Kapsel nach einem der Ansprüche 1 bis 10, bei welcher die zweite Öffnung in dem zweiten Teil ausgebildet ist.
  12. Kapsel nach den Ansprüchen 10 und 11, bei welcher der zweite Teil ein Hülsenteil mit einem inneren Durchgang (21) ist, welcher die erste und die zweite Öffnung verbindet.
  13. Kapsel nach Anspruch 12, bei welcher die erste Öffnung durch eine Einschränkung (25) in dem Durchgang ausgebildet ist.
  14. Kapsel nach Anspruch 13, bei welcher die Einschränkung durch eine nach innen gerichtete Schulter (25) in dem Durchgang ausgebildet ist.
  15. Kapsel nach einem der Ansprüche 12 bis 14, bei welcher die zweite Öffnung an einem Ende des inneren Durchgangs ausgebildet ist.
  16. Kapsel nach einem der Ansprüche 1 bis 15, bei welcher der erste Teil in dem zweiten Teil für eine Gleitbewegung relativ zu ihm montiert ist.
  17. Kapsel nach einem der Ansprüche 1 bis 16, bei welcher die innere Kammer zwischen dem ersten und dem zweiten Teil definiert ist.
  18. Kapsel nach einem der Ansprüche 12 bis 17, bei welcher der erste Teil in dem Durchgang gleitbar montiert ist, und die innere Kammer zwischen der inneren Oberfläche des Durchgangs und der äußeren Oberfläche des ersten Teils definiert ist.
  19. Kapsel nach einem der Ansprüche 1 bis 18, wobei sich der erste Teil in dem Füllzustand durch die zweite Öffnung erstreckt, um einen Spalt dazwischen für einen Eintritt des mitgerissenen Pulvers in die innere Kammer zu lassen, und wobei der erste Teil in dem Dichtzustand in eine abdichtende Beziehung in der zweiten Öffnung bewegt ist.
  20. Kapsel nach Anspruch 19, bei welcher der erste Teil einen Kappenabschnitt (39) aufweist, welcher, in dem Füllzustand, außerhalb der zweiten Öffnung beabstandet ist, aber welcher in dem Dichtzustand abdichtend in der zweiten Öffnung sitzt.
  21. Kapsel nach Anspruch 20, bei welcher der erste Teil einen Schenkelabschnitt (29) aufweist, der den Kappenabschnitt mit dem Stöpselabschnitt verbindet.
  22. Kapsel nach einem der Ansprüche 1 bis 21, bei welcher der erste und der zweite Teil weiter relativ zueinander bewegbar sind, um den Körper aus dem Dichtzustand in einen Abgabezustand zu bringen, in welchem ein Luftstrom von der ersten Öffnung zu der zweiten Öffnung durch den Körper erzeugt werden kann, um das Pulver in der inneren Kammer in die äußere Umgebung mitzureißen.
  23. Kapsel nach Anspruch 22, wobei der erste Teil einen Abschnitt mit einer transversalen Abmessung aufweist, welche weniger als die entsprechende Abmessung des Stöpselabschnitts beträgt, wobei sich der Abschnitt in Bezug auf den Stöpselabschnitt derart befindet, dass er in dem Abgabezustand in Passgenauigkeit mit der ersten Öffnung gebracht ist.
  24. Kapsel nach einem der vorhergehenden Ansprüche, mit einem inhalierbaren pharmazeutischen Pulver in der inneren Kammer.
  25. Kapsel nach Anspruch 24, mit einer Einheitsdosis des inhalierbaren pharmazeutischen Pulvers in der inneren Kammer.
  26. Kapsel nach einem der vorhergehenden Ansprüche, bei welcher die innere Kammer die einzige innere Kammer ist.
  27. Kapsel nach einem der vorhergehenden Ansprüche, bei welcher die Nuten oder Rillen eine Tiefe von 0,007mm aufweisen.
  28. Inhalationsvorrichtung mit einer oder mehr Kapseln nach Anspruch 25 oder 26.
EP08152808.5A 2002-11-20 2003-11-18 Kapsel für Pulvermedikament Expired - Lifetime EP1930041B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0227128.6A GB0227128D0 (en) 2002-11-20 2002-11-20 A capsule
EP03795835A EP1562662B1 (de) 2002-11-20 2003-11-18 Verfahren zum Bereitstellen einer Kapsel mit einem Pulverarzneimittel

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP03795835A Division EP1562662B1 (de) 2002-11-20 2003-11-18 Verfahren zum Bereitstellen einer Kapsel mit einem Pulverarzneimittel

Publications (3)

Publication Number Publication Date
EP1930041A2 EP1930041A2 (de) 2008-06-11
EP1930041A3 EP1930041A3 (de) 2008-08-20
EP1930041B1 true EP1930041B1 (de) 2017-12-20

Family

ID=9948219

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03795835A Expired - Lifetime EP1562662B1 (de) 2002-11-20 2003-11-18 Verfahren zum Bereitstellen einer Kapsel mit einem Pulverarzneimittel
EP08152808.5A Expired - Lifetime EP1930041B1 (de) 2002-11-20 2003-11-18 Kapsel für Pulvermedikament

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03795835A Expired - Lifetime EP1562662B1 (de) 2002-11-20 2003-11-18 Verfahren zum Bereitstellen einer Kapsel mit einem Pulverarzneimittel

Country Status (9)

Country Link
US (2) US7713518B2 (de)
EP (2) EP1562662B1 (de)
JP (1) JP2006506144A (de)
AT (1) ATE389431T1 (de)
AU (1) AU2003298133A1 (de)
DE (1) DE60319864T2 (de)
ES (1) ES2659540T3 (de)
GB (1) GB0227128D0 (de)
WO (1) WO2004045688A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
GB0227128D0 (en) 2002-11-20 2002-12-24 Glaxo Group Ltd A capsule
GB0308969D0 (en) 2003-04-17 2003-05-28 Glaxo Group Ltd Capsules
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US8763605B2 (en) * 2005-07-20 2014-07-01 Manta Devices, Llc Inhalation device
ES2640282T3 (es) 2005-09-14 2017-11-02 Mannkind Corporation Método de formulación de fármacos basado en el aumento de la afinidad de superficies de micropartículas cristalinas para agentes activos
AU2007210177C1 (en) 2006-01-31 2012-11-01 Oriel Therapeutics, Inc. Dry powder inhalers having spiral travel paths, unit dose microcartridges with dry powder, related devices and methods
CA2643464C (en) 2006-02-22 2018-09-04 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
AT504991B1 (de) * 2007-02-23 2009-04-15 Rouven Mag Haas Vorrichtung zur oralen einnahme von lebensmitteln und/oder genussmitteln und/oder nichtinhalativen medikamenten
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation
WO2009009013A2 (en) 2007-07-06 2009-01-15 Manta Devices, Llc Inhalation devices for storing and delivering medicament
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
PT2230934E (pt) 2007-12-14 2012-11-20 Aerodesigns Inc Distribuir produtos alimentares aerossolizáveis
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
IL279542B2 (en) * 2008-06-13 2023-10-01 Mannkind Corp Dry powder inhaler and drug delivery system
EP2300083B1 (de) 2008-06-20 2013-05-22 MannKind Corporation Interaktives gerät und verfahren für die echtzeit-profilierung von inhalationsversuchen
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
USD666493S1 (en) 2010-11-01 2012-09-04 Colgate-Palmolive Company Cap for a container
USD666096S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666099S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666098S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666097S1 (en) 2010-11-01 2012-08-28 Colgate-Palmolive Company Cap for a container
USD666492S1 (en) 2010-11-01 2012-09-04 Colgate-Palmolive Company Cap for a container
JP5960726B2 (ja) * 2011-01-31 2016-08-02 株式会社新日本科学 鼻腔内送達デバイス
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
WO2014165334A1 (en) 2013-04-03 2014-10-09 United Technologies Corporation Dynamic method of obtaining a sample of materials
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3137140B1 (de) 2014-05-02 2019-07-10 Manta Devices, LLC Ausgabevorrichtung
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN113329779B (zh) * 2019-01-14 2023-08-08 菲利普莫里斯生产公司 干粉吸入器
DE102020100550A1 (de) * 2019-01-14 2020-07-16 Alfred Von Schuckmann Vorrichtung zum Inhalieren pulverförmiger Substanzen, Substanzbehälter für eine solche Vorrichtung sowie Verfahren zum Befüllen einer derartigen Vorrichtung

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US330970A (en) * 1885-11-24 Cliffoed
US1410556A (en) * 1919-03-07 1922-03-28 Frank C Dorment Inhaler
GB367560A (en) 1930-02-17 1932-02-25 Ernest Guiraud Improvements in or relating to apparatus for giving warning of the approach of trains
GB367580A (en) * 1931-03-07 1932-02-25 Ronald Hayden Linton Mouth or nasal medicament inhalers
US2103520A (en) 1934-04-20 1937-12-28 Samuel E Witt Dispenser for tablets or the like
US2642063A (en) * 1948-07-31 1953-06-16 Frederick M Turnbull Inhaler
US2590832A (en) * 1949-03-29 1952-03-25 Frederick M Turnbull Inhaler with closure
US2587215A (en) 1949-04-27 1952-02-26 Frank P Priestly Inhalator
DE837157C (de) * 1950-07-16 1952-04-21 Karl Mende Inhalator
US2645063A (en) * 1951-05-28 1953-07-14 Richard B Smith Blade sharpening device
CH371528A (de) 1959-09-19 1963-08-31 Escher Wyss Ag Vorrichtung zur Regelung eines Kernreaktors
JPS5555745Y2 (de) 1975-12-22 1980-12-24
IE50472B1 (en) 1979-10-30 1986-04-30 Riker Laboratories Inc Breath actuated devices for administering powdered medicaments
US4265236A (en) * 1980-03-31 1981-05-05 Pacella Angelo M Portable inhalator device
US4391590A (en) 1981-04-09 1983-07-05 Dentsply Research & Development Corp. Cartridge for viscous material
GB8516527D0 (en) 1985-06-29 1985-07-31 Filhol S J Packaging system
JPS62122901A (ja) * 1985-11-13 1987-06-04 株式会社資生堂 粉粒状物品の充填方法
US4767326A (en) 1986-11-25 1988-08-30 Dentsply Research & Development Corp. Cartridge container and ejector piston therefor
CH676796A5 (de) 1987-09-09 1991-03-15 Henri Dr Med Siegenthaler
IT1228460B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore monouso con capsula pre-forata
IT1230313B (it) 1989-07-07 1991-10-18 Somova Spa Inalatore per medicamenti in capsule.
DE69211450T2 (de) 1991-08-16 1996-12-05 Sandoz Ag Inhalator zur Verabreichung von pulverförmigen Substanzen
US5287850A (en) 1991-08-20 1994-02-22 Habley Medical Technology Corporation Timing and velocity controlled powered pharmaceutical inhaler
FR2686508B1 (fr) 1992-01-29 1994-04-08 Phystor Appareil distributeur de medicaments en forme de gelule ou de pilule.
GB9203761D0 (en) 1992-02-21 1992-04-08 Innovata Biomed Ltd Inhaler
GB9216038D0 (en) 1992-07-28 1992-09-09 Bespak Plc Dispensing apparatus for powdered medicaments
GB2270293A (en) 1992-09-05 1994-03-09 Medix Ltd Drug dispensing system
US5896855A (en) 1992-12-24 1999-04-27 Rhone-Poulenc Rorer Limited Multi dose inhaler apparatus
US5372128A (en) 1993-04-14 1994-12-13 Habley Medical Technology Corporation Fluidizing powder inhaler
DK0714314T3 (da) 1993-08-18 1999-06-23 Fisons Plc Inhalator med åndedrætsregulering
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
GB9409852D0 (en) 1994-05-17 1994-07-06 Cambridge Consultants Device for administering single doses of a medicament
GB9409851D0 (en) * 1994-05-17 1994-07-06 Cambridge Consultants Improvements in and relating to containers of particulate material
IT1276916B1 (it) 1995-10-12 1997-11-03 Istoria Farmaceutici S P A Dispositivo per il trattamento di pazienti asmatici, atto a misurare il picco di flusso espiratorio e ad erogare farmaci per il
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
US6470884B2 (en) 1996-01-29 2002-10-29 Aventis Pharma Limited Capsule opening arrangement for use in a powder inhaler
GB9705071D0 (en) 1997-03-12 1997-04-30 Theobald David R Nebuliser
KR19980075693A (ko) 1997-03-31 1998-11-16 배순훈 써미스터를 이용한 멀티가습기의 진동자 보호방법
PT101988B (pt) 1997-04-04 2004-02-27 Hovione Farmaciencia Sa Sistema de orientacao e posicionamento de um objecto
GB9810126D0 (de) * 1998-05-13 1998-07-08 Glaxo Group Ltd
GB9809933D0 (en) 1998-05-08 1998-07-08 Cambridge Consultants Drug delivery device
CA2335569C (en) 1998-07-01 2009-05-19 F. Dewitt Reed Jr. Vehicle for and methods of administering volatile substances into an inhalation flow path
GB2340758A (en) 1998-08-21 2000-03-01 Bespak Plc Drug dispensing system
JP2000217917A (ja) * 1999-01-27 2000-08-08 Unisia Jecs Corp 吸入式投薬器
EP1923087B1 (de) 1999-07-23 2012-09-05 MannKind Corporation Einheitsdosenkapseln für Trockenpulverinhalator
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
SE9903824D0 (sv) 1999-10-22 1999-10-22 Medifront Ab Anordning för avgivning av multipla doser för pulverinhalatorer och motsvarande avgivningsförfarande
WO2001030430A1 (en) 1999-10-22 2001-05-03 Innovata Biomed Limited Dosage unit for dry powder medicament
US6503084B2 (en) 2000-02-24 2003-01-07 Dentsply Detrey G.M.B.H. Method for dispensing dental materials
AU2001283546A1 (en) 2000-08-14 2002-02-25 Advanced Inhalation Research, Inc. Inhalation device and method
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
US6595210B2 (en) * 2000-11-27 2003-07-22 Unisia Jecs Corporation Inhalator for administering powder composition
DE60120105D1 (de) 2001-03-28 2006-07-06 Pera Ivo E Stiftförmige Inhalationsvorrichtung zur Abgabe von pulverförmigen Medikamenten in den Atmungstrakt
GB0112888D0 (en) 2001-05-26 2001-07-18 Innovata Biomed Ltd Device
GB0113881D0 (en) 2001-06-07 2001-08-01 Innovate Biomed Ltd Foil cutting system
WO2003030974A1 (en) 2001-10-08 2003-04-17 Eli Lilly And Company Portable medication inhalation kit
GB0125134D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Medicament dispenser
ATE332162T1 (de) 2001-11-22 2006-07-15 Raul Goldemann Atemzugskontrollierte inhalationsvorrichtung für trockenpulver
US6684917B2 (en) * 2001-12-17 2004-02-03 The University Of Western Ontario Apparatus for volumetric metering of small quantity of powder from fluidized beds
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
US6708884B1 (en) 2002-06-25 2004-03-23 The United States Of America As Represented By The Secretary Of The Army Method and apparatus for rapid and precision detection of omnidirectional postnet barcode location
GB0227128D0 (en) 2002-11-20 2002-12-24 Glaxo Group Ltd A capsule

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
DE60319864D1 (de) 2008-04-30
US20060062740A1 (en) 2006-03-23
EP1930041A3 (de) 2008-08-20
GB0227128D0 (en) 2002-12-24
ES2659540T3 (es) 2018-03-16
US20100175698A1 (en) 2010-07-15
WO2004045688A1 (en) 2004-06-03
DE60319864T2 (de) 2009-04-23
EP1562662A1 (de) 2005-08-17
EP1930041A2 (de) 2008-06-11
US8668928B2 (en) 2014-03-11
EP1562662B1 (de) 2008-03-19
ATE389431T1 (de) 2008-04-15
JP2006506144A (ja) 2006-02-23
AU2003298133A1 (en) 2004-06-15
US7713518B2 (en) 2010-05-11

Similar Documents

Publication Publication Date Title
EP1930041B1 (de) Kapsel für Pulvermedikament
US8201555B2 (en) Inhaler
EP2142239B1 (de) Inhaliergerät
EP2526990A2 (de) Trockenes Pulver zur Inhalation
US6886612B2 (en) Method and apparatus for transferring a defined quantity of powder
MX2011003245A (es) Inhaladores de polvo seco con mecanismos de perforacion giratorios y dispositivos y metodos relacionados.
EP1490263B1 (de) Verfahren und vorrichtung zum abfüllen eines behälters mit einem produkt
US20070131225A1 (en) Hand-Held Capsule Device
US20060076010A1 (en) Drug delivery system with vented mouthpiece
EP1613379B1 (de) Durch ketten verknüpfte kapseln
CN111315432B (zh) 吸入器和用于吸入器的网格
US20070163582A1 (en) Hand-held capsule device
AU2007203143A1 (en) Method and apparatus for loading a container with a product

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080314

AC Divisional application: reference to earlier application

Ref document number: 1562662

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 15/00 20060101AFI20080430BHEP

Ipc: A61M 15/06 20060101ALI20080717BHEP

17Q First examination report despatched

Effective date: 20080925

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AXX Extension fees paid

Extension state: LV

Payment date: 20080314

Extension state: LT

Payment date: 20080314

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXO GROUP LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170713

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1562662

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 955807

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60350867

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2659540

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180316

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 955807

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60350867

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181118

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20031118

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20201023

Year of fee payment: 18

Ref country code: GB

Payment date: 20201029

Year of fee payment: 18

Ref country code: IT

Payment date: 20201118

Year of fee payment: 18

Ref country code: ES

Payment date: 20201202

Year of fee payment: 18

Ref country code: DE

Payment date: 20201013

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60350867

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20211118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211118

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211118

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211119